Introduction {#s1}
============

Ulcerative colitis (UC) is characterized by mucosal ulceration, rectal bleeding, diarrhea and abdominal pain. Current drug treatments for UC include aminosalicylic acid (5-ASA), corticosteroids, azathioprine and/or antagonists against tumor necrosis factor (TNF)-α or integrin α4β7 \[[@R01]-[@R05]\]. Studies have demonstrated the efficacy and safety of tofacitinib (TOF), which is a pan-Janus kinase (JAK) inhibitor, for the treatment of moderate to severe UC patients who failed to achieve clinical remission, did not respond to conventional medications, or lost response to TNF-α antagonists \[[@R06]\]. However, the reported efficacy rates of TOF monotherapy in inducing clinical remission in randomized patients with refractory UC were 18.5% in the Oral Clinical Trials for Tofacitinib in Ulcerative Colitis (OCTAVE) induction 1 trial and 16.6% in the OCTAVE induction 2 trial at 8 weeks \[[@R06]\]. Therefore, the use of TOF monotherapy has been limited when higher induction remission rates are the goal.

On the other hand, granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn^®^ (JIMRO, Takasaki, Japan) is another effective and safe therapeutic option for patients with mild to moderate UC refractory to pharmacological therapy \[[@R07]\]. Furthermore, intensive GMA of two sessions per week has been recently shown to be superior to routine weekly GMA, both in remission rate and time to remission in patients with refractory UC \[[@R08]\]. However, the efficacy of intensive GMA on induction of clinical remission in patients with severe UC has not been satisfactory \[[@R9]\]. In this study, we retrospectively assessed the 10-week efficacy of a combination therapy with TOF and intensive GMA on patients with refractory UC.

Patients and Methods {#s2}
====================

Patients {#s2a}
--------

Between December 2018 and November 2019, seven consecutive patients with moderate and severe UC were recruited from Nagoya City University Hospital and Midori Municipal Hospital for the study. Patients with UC who received a combination therapy with TOF and intensive GMA were enrolled in this study, according to the following criteria: 1) refractory or dependent on corticosteroids or loss of response to TNF-α antagonists; and 2) moderate to severe UC, with a Mayo score of 6 to 12 at baseline, including an endoscopic subscore of 2 to 3, despite concurrent treatment with corticosteroids and/or TNF-α antagonists and 5-ASA. Only the dosages of corticosteroids were tapered off as appropriate. TOF was administered at 10 mg twice a day for 8 weeks as induction therapy and, subsequently, 5 mg twice a day, and intensive GMA was administered in two sessions a week for a total of 10 times. The study protocol was approved by Nagoya City University ethics committee as a representative of both the hospitals (\#60-19-0164), and written informed consent was obtained from all patients prior to enrollment.

Treatment and assessments {#s2b}
-------------------------

The primary outcome was the 10-week clinical remission rate of the combination therapy with TOF and intensive GMA, and the secondary outcomes were the rates of clinical response and mucosal healing at 10 weeks. Disease activity and severity were assessed using the full Mayo score \[[@R02]\] at baseline and at 10 weeks. Mucosal healing was defined as a Mayo endoscopy subscore of either 0 or 1, and complete mucosal healing was defined as a subscore of 0. Clinical remission was defined as a Mayo score of ≤ 2 with no individual subscore of \> 1. Any adverse event, including the date of onset, severity, outcome and relationship of events with the therapy, was recorded.

Statistical methods {#s2c}
-------------------

The data were presented as means ± standard error of the mean, and comparisons were made by using paired *t*-test. Statistical analyses were performed by SPSS V24 software. A significant level of 0.01 was used for all statistical tests, and two-tailed tests were applied as appropriate.

Results {#s3}
=======

The demographic data are shown in [Table 1](#T1){ref-type="table"}. The mean age was 53.3 years, and the mean disease duration was 16.1 years. In terms of colonic involvement, three had extensive colitis and four had left-sided colitis. The concurrent medications included 5-ASA, corticosteroids and TNF-α antagonists. Of seven patients, two were corticosteroid-refractory, five were corticosteroid-dependent and four experienced loss of response to TNF-α antagonists. The mean full Mayo score and C-reactive protein (CRP) levels at baseline were 8.71 and 0.71 mg/dL ([Table 1](#T1){ref-type="table"}).

###### Baseline Demographic Data of Seven Cases That Received Combination Therapy With TOF and Intensive GMA for Refractory UC

  Demography                               
  ---------------------------------------- ------
  Male/female (N)                          2/5
  Age (years)                              53.3
  Mean disease duration (years)            16.1
  Location of lesions (N)                  
    Extensive                              3
    Left-sided                             4
  Severity (N)                             
    Moderate/severe                        6/1
  Concomitant medications for UC (N)       
    Corticosteroids/budesonide             6
    Mesalamine                             7
    Azathioprine                           1
  Prior use of anti-TNF-α antibodies (N)   4
  Full Mayo score at baseline              8.71
  Endoscopic sub-score at baseline         2.4
  CRP at baseline (mg/dL)                  0.71

The data are presented as means. TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; UC: ulcerative colitis; TNF: tumor necrosis factor; CRP: C-reactive protein.

Among the seven patients who were given a combination therapy of TOF and intensive GMA, the mean full Mayo scores decreased from 8.71 ± 0.80 at baseline to 1.57 ± 0.48 at 10 weeks, and mean endoscopic subscore decreased from 2.4 ± 0.2 at baseline to 0.6 ± 0.2 at 10 weeks ([Fig. 1a, b](#F1){ref-type="fig"}). These improvements were significant (P \< 0.01). On the other hand, the mean CRP level decreased from 0.71 ± 0.49 mg/dL at baseline to 0.02 ± 0.005 mg/dL at 10 weeks with no significant difference (P = 0.20) after the combination therapy with TOF and intensive GMA ([Fig. 1c](#F1){ref-type="fig"}). The rate of clinical remission at 10 weeks was 71.4%. At 10 weeks, mucosal healing was observed in all cases (100%) and complete mucosal healing \[[@R10]\] was seen in three cases (42.9%). In addition, all six patients who received oral prednisolone or rectal budesonide were able to withdraw corticosteroids at 10 weeks (100%) ([Table 2](#T2){ref-type="table"}).

![Clinical outcomes at baseline and at 10 weeks in seven patients who received combination therapy TOF and intensive GMA. The mean full Mayo scores (a) and endoscopic sub-scores (b) show significant differences between at baseline and 10 weeks (P \< 0.01). The mean full Mayo scores decreased from 8.71 ± 0.80 at baseline to 1.57 ± 0.48 at 10 weeks, and the mean endoscopic subscore decreased from 2.4 ± 0.2 at baseline to 0.6 ± 0.2 at 10 weeks. CRP values (c) show no significant difference between at baseline and 10 weeks (P = 0.20). The mean CRP level decreased from 0.71 ± 0.49 mg/dL at baseline to 0.02 ± 0.005 mg/dL at 10 weeks. The values are presented as means ± standard error values and were made by using paired *t*-test. \*P\< 0.01. TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; CRP: C-reactive protein.](jocmr-12-036-g001){#F1}

###### Clinical Course Through 10 Weeks

  No.   Age   Sex   Disease duration (years)   Disease location   Pretreated   At baseline   Treated   At 10 weeks                                        
  ----- ----- ----- -------------------------- ------------------ ------------ ------------- --------- ------------- ------ ---- ---- --- --- ---- ------ ---
  1     70    M     10                         Left-sided         IFX          40            12        3             3.56   \+   \+   0   0   \+   0.04   0
  2     40    M     4                          Extensive          ADA          40            10        2             0.99   \+   \+   1   1   \+   0.04   0
  3     45    F     29                         Left-sided         IFX          0             6         3             0.03   \+   \+   3   1   \-   0.03   0
  4     58    F     22                         Extensive                       3             7         2             0.04   \+   \+   3   0   \-   0.03   0
  5     64    F     32                         Left-sided                      5             9         3             0.16   \+   \+   2   1   \+   0.01   0
  6     50    F     6                          Left-sided         ADA, AZA     Bude 2        7         2             0.04   \+   \+   2   1   \+   0.01   0
  7     46    F     10                         Extensive                       20            10        2             0.2    \+   \+   0   0   \+   0.01   0

PSL: prednisolone; Bude: budesonide; CRP: C-reactive protein; ADA: adalimumab; IFX: infliximab; TOF: tofacitinib; GMA: granulocyte and monocyte adsorptive apheresis; CR: clinical remission; AZA: azathioprine.

Safety {#s3a}
------

Adverse events were observed in three patients: one had orolabial herpes, one had transient increase in creatinine phosphokinase due to intense physical exercise and one had triglyceride increase. In these cases, TOF was not discontinued and 10 sessions of intensive GMA were completed. In general, combination therapy with TOF and intensive GMA was safe and well tolerated.

Discussion {#s4}
==========

In this study, we reported the efficacy of a combination of TOF induction and intensive GMA in seven consecutive cases of refractory UC.

TOF is a small oral molecule and is a pan-JAK inhibitor that suppresses the JAK signal transducers and the activators of transcription pathway, thereby down-regulating the expressions of multiple immune-relevant mediators and inflammatory cytokines that are implicated in the pathogenesis of inflammatory bowel disease (IBD) \[[@R11], [@R12]\]. In the clinical setting, TOF has been an efficacious therapy to induce clinical remission in patients with moderate to severe active UC \[[@R06], [@R13]\]. Two phase 3 trials that investigated TOF as induction therapy, the OCTAVE induction 1 and 2, which were double-blind placebo-controlled phase 3 trials that investigated TOF as induction therapy, revealed that the overall clinical remission rate at week 8 was 18.5% in patients who were randomized to TOF at a dose of 10 mg twice a day; and 8.2% in patients allocated to placebo (P = 0.007) in the OCTAVE induction 1 trial; 16.6% in patients who were randomized to TOF at a dose of 10 mg twice a day; and 3.6% in patients allocated to placebo (P \< 0.001) in the OCTAVE induction 2 trial. Therefore, TOF monotherapy for refractory UC has limitation, and additional treatment would be necessary for active UC patients who are biologically naive and have lost response to TNF-α antagonists. In the present study on seven patients who received combination therapy with TOF plus intensive GMA, the rate of clinical remission at 10 weeks was 71.4%. Based on this outcome, the addition of intensive GMA to TOF monotherapy appeared to be an effective therapy that induced clinical remission.

In Europe and Japan, GMA is available for the treatment of patients with active IBD that has become refractory to standard drug-based medications, including TNF-α blockers. GMA depletes the elevated and activated myeloid lineage of leukocytes and has been associated with marked downregulation of inflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-8 and TNF-α, which are released by myeloid leukocytes and lymphocytes, most likely through an upstream mechanism that involves the adsorption of cytokine-producing cells \[[@R14], [@R15]\]. Furthermore, in patients with active UC, downregulation of the leukocyte adhesion molecule L-selectin and neutrophil adhesion to endothelial cells activated by IL-1β were observed after *in vitro* exposure of peripheral blood to G-1 beads that composed a main part of Adacolumn \[[@R16]\]. These suggested that the combination therapy worked by drastically downregulating the circulating inflammatory cytokines and the expressions of adhesive molecules on the activated granulocytes, which was an effect of GMA, and by downregulating the local inflammatory cytokines at the microenvironmental sites in the gut mucosa, which was an effect of TOF, thereby, inducing rapid clinical remission \[[@R17], [@R18]\]. In addition, serious adverse side effects have been rare in patients receiving GMA \[[@R9], [@R19]\].

Endoscopic evaluation of patients who received TOF for refractory UC showed significant (P \< 0.001) 8-week mucosal healing rates of 31.3% (vs. 15.6% in the placebo) in the OCTAVE induction 1 trial and 28.4% (vs. 11.6% in the placebo) in the OCTAVE induction 2 trial. In the present study on seven patients who received a combination therapy of TOF and intensive GMA, the rate of mucosal healing at 10 weeks was 100% and that of complete mucosal healing rate was 42.9%. The mean endoscopic subscore was significantly lower at 10 weeks than at baseline. Based on these outcomes, addition of intensive GMA to TOF monotherapy appeared to be effective in inducing mucosal healing \[[@R17], [@R18]\]. An additional study on a large cohort of patients is warranted to verify this finding.

Increased risks for hematologic disorders; opportunistic infections, including Herpes zoster; and elevation in CK or lipid levels have been reported with the use of TOF \[[@R06]\]. In the present study, orolabial herpes and increase in CK and triglycerides were seen in three cases, respectively. These were consistent with the adverse events reported in the OCTAVE induction 1 and 2 trials. The present study has limitations on sample size and exposure time to fully characterize the safety of combination therapy of TOF and intensive GMA.

In conclusion, combination therapy with TOF and intensive GMA was well tolerated and may be useful for the induction of clinical remission and mucosal healing in patients with refractory UC.
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